Establishment of a novel gene panel as a biomarker of immune checkpoint inhibitor response.

ABSTRACT:

Objective

Immune checkpoint inhibitors (ICIs) have become the standard of care in various cancers, although the predictive tool is still unknown.

Methods

This study aimed to develop a novel gene panel by selecting DNA damage response (DDR) genes from the Catalogue of Somatic Mutations in Cancer (COSMIC) databank and validating them in previously reported cohorts. This association between DDR gene mutations and tumor mutation burden or microsatellite status was analysed from The Cancer Genome Atlas (TCGA) databank. Furthermore, we made the gene panel clinically accessible and predicted the response in clinical patients receiving ICIs by using cell-free DNA.

Results

The top 20 mutated DDR genes in various cancers (total 37 genes) were taken from the COSMIC databank, and

SUBMITTER: Pan YR 

PROVIDER: S-EPMC7326616 | biostudies-literature | 2020

REPOSITORIES: biostudies-literature